- Home
- OPRA vs IMCR Comparison
OPRA vs IMCR Comparison
Compare OPRA & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPRA | IMCR |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | Norway | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | OPRA | IMCR |
|---|---|---|
| Price | $19.29 | $32.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $21.50 | ★ $66.33 |
| AVG Volume (30 Days) | 335.1K | ★ 648.0K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $21.29 | $14.57 |
| Revenue Next Year | $15.34 | $8.21 |
| P/E Ratio | ★ $13.62 | $132.32 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $11.71 | $27.56 |
| 52 Week High | $21.06 | $40.71 |
Technical Indicators
Market Signals| Indicator | OPRA | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 57.21 |
| Support Level | $16.96 | $31.02 |
| Resistance Level | $19.43 | $33.32 |
| Average True Range (ATR) | 0.71 | 1.34 |
| MACD | -0.02 | 0.25 |
| Stochastic Oscillator | 51.41 | 64.12 |
Price Performance
Historical ComparisonAbout OPRA Opera Limited
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.